Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Essential Thrombocythemia Therapy

NCT01192347 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01192347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01192347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Essential Thrombocythemia Therapy
Lead sponsor
Shire
Phase
Observational
Overall status
Completed
Start date
September 13, 2010
Completion date
December 21, 2012
Enrollment
177 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia